ArticleInfectious diseases of poverty2018
Mapping and modelling the impact of mass drug adminstration on filariasis prevalence in Myanmar.
Article in Infectious diseases of poverty, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Individual longitudinal compliance to neglected tropical disease mass drug administration programmes, a systematic review.PLoS neglected tropical diseases · 2023Pooled it
- Lymphatic filariasis in Asia: a systematic review and meta-analysis.Parasitology research · 2021Pooled it
- Sociodemographic determinants of lymphatic filariasis knowledge among refugees in Cameroon.Discover public health · 2026Article
- Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania.CPT: pharmacometrics & systems pharmacology · 2023Article
- Lymphatic filariases and soil-transmitted helminthiases in Sri Lanka: the challenge of eliminating residual pockets of transmission.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Review
- Community engagement in health services research on elimination of lymphatic filariasis: A systematic review.PLOS global public health · 2023Article
- Bayesian Network Analysis of Lymphatic Filariasis Serology from Myanmar Shows Benefit of Adding Antibody Testing to Post-MDA Surveillance.Tropical medicine and infectious disease · 2022Article
- Progress and impact of 20 years of a lymphatic filariasis elimination programme in South-East Asia.International health · 2020Article
- Achievements and challenges of lymphatic filariasis elimination in Sierra Leone.PLoS neglected tropical diseases · 2020Article
- Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana.PLoS neglected tropical diseases · 2020Article
- Neglected tropical diseases: an effective global response to local poverty-related disease priorities.Infectious diseases of poverty · 2020Review
- Developing the first national database and map of lymphatic filariasis clinical cases in Bangladesh: Another step closer to the elimination goals.PLoS neglected tropical diseases · 2019Article
- Preventive chemotherapy reverses covert, lymphatic-associated tissue change in young people with lymphatic filariasis in Myanmar.Tropical medicine & international health : TM & IH · 2019Article
- Mapping and monitoring for a lymphatic filariasis elimination program: a systematic review.Research and reports in tropical medicine · 2019Review
- Emerging neglected helminthiasis and determinants of multiple helminth infections in flood-prone township in Myanmar.Tropical medicine and health · 2019Article
- The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar.PLoS neglected tropical diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphatic filariasis (LF) is endemic in Myanmar and targeted for elimination. To highlight the National Programme to Eliminate Lymphatic Filariasis (NPELF) progress between 2000 and 2014, this paper describes the geographical distribution of LF, the scale-up and impact of mass drug administration (MDA) implementation, and the first evidence of the decline in transmission in five districts.
methodsThe LF distribution was determined by mapping historical and baseline prevalence data collected by NPELF. Data on the MDA implementation, reported coverage rates and sentinel site surveillance were summarized. A statistical model was developed from the available prevalence data to predict prevalence at township level by year of measurement. Transmission assessment survey (TAS) methods, measuring antigenemia (Ag) prevalence in children, were used to determine whether prevalence was below a level where recrudescence is unlikely to occur.
resultsThe highest baseline LF prevalence was found in the Central Valley region. The MDA implementation activities scaled up to cover 45 districts, representing the majority of the endemic population, with drug coverage rates ranging from 60.0% to 98.5%. Challenges related to drug supply and local conflict were reported, and interrupted MDA in some districts. Overall, significant reductions in LF prevalence were found, especially after the first 2 to 3 rounds of MDA, which was supported by the corresponding model. The TAS activities in five districts found only two Ag positive children, resulting in all districts passing the critical threshold.
conclusionOverall, the Myanmar NPELF has made positive steps forward in the elimination of LF despite several challenges, however, it needs to maintain momentum, drawing on international stakeholder support, to aim towards the national and global goals of elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.